Search tips
Search criteria 


Logo of annaldermaAnnals of DermatologyThis ArticleInformation for AuthorsOnline Submission
Ann Dermatol. 2012 August; 24(3): 295–305.
Published online 2012 July 25. doi:  10.5021/ad.2012.24.3.295
PMCID: PMC3412238

The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

Jae-Hong Kim, M.D., Sung Yul Lee, M.D., Hae-Jin Lee, M.D., Na-Young Yoon, M.D., and Won-Soo Lee, M.D., Ph.D.corresponding author



There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cranell® alpha 0.025%) solution to Korean female patients with FPHL.


This study was designed to examine the efficacy and safety of Ell-Cranell® alpha 0.025% solution in Korean female patients with FPHL.


A total of 53 women, 18 to 55 years old, applied topical Ell-Cranell® alpha 0.025% solution once daily for 8 months. Efficacy was evaluated by the change of hair counts and diameter, subjective assessment, and photographic assessment by investigators.


Hair counts and diameter from baseline to 4 and 8 months after treatment increased in treated patients and these changes were statistically significant (p<0.0001). 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by subjective self-assessment and by investigator photographic assessment. Ell-Cranell® alpha 0.025% solution was well tolerated over 8-months period.


This study showed that Ell-Cranell® alpha 0.025% solution is a safe and effective agent for Korean women with FPHL.

Keywords: 17α-estradiol, Ell-Cranell®, Female pattern hair loss

Articles from Annals of Dermatology are provided here courtesy of Korean Dermatological Association and Korean Society for Investigative Dermatology